Coronary AngiographyREPEATNCT05340998
Radial accEss Crossover for PErcutaneous Coronary Procedures And ouTcome: the REPEAT Study
An observational study of Coronary Angiography and Percutaneous Coronary Intervention, run by Ospedale Sandro Pertini, Roma at 10 sites in Italy.
Trial summary
All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial access (TRA) will be screened for inclusion in this prospective observational study and patients with TRA failure necessitating vascular crossover will be included in the Registry after signing a dedicated… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Angiography, Percutaneous Coronary Intervention
- What is being tested?
- Transradial access for percutaneous coronary procedures
- Type of treatment
- Surgery or procedure
- How many people
- 1,357 participants
- Where
- 10 sitesItaly
- Study dates
- 15 Jul 2022to 16 Jan 2025
- How long will I take part?
- 6 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with an indication to percutaneous coronary procedures performed through transradial approach
Who may be able to join
- All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial access
Who cannot join
- Lack of signed informed consent, age <18 years
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
Italy10 sites
Ospedale di Avezzano
Avezzano
Ospedale S. Andrea
Roma
Ospedale S. Camillo
Roma
Ospedale Sandro Pertini
Roma
Ospedale Santo Spirito
Roma
Policlinico Agostino Gemelli
Roma
Policlinico Umberto I
Roma
Ospedale di Sassari
Sassari
Ospedale di Teramo
Teramo
Ospedale di Trento
Trento
About this study
All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial access (TRA) will be screened for inclusion in this prospective observational study and patients with TRA failure necessitating vascular crossover will be included in the Registry after signing a dedicated written informed consent. A Control group of consecutive patients with radial access and without crossover will be included. Primary end point of the study is the rate of in-hospital vascular complications and major bleeding in crossover vs non crossover groups
Read the detailed description
All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial approach (TRA) will be screened for inclusion in this prospective observational study and patients with TRA failure necessitating vascular crossover will be included in the Registry after signing a dedicated written informed consent. A Control group of consecutive patients with radial access and without crossover will be enrolled (2:1 rate compared to crossover group to avoid possible selection bias) after signing a dedicated written informed consent.
The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion.
According to the selected secondary access, patients will be divided in two groups: patients with a secondary (or tertiary) wrist access (total wrist Group) and patients with a crossover to femoral (Femoral Group). Patients included in the total wrist group may have a secondary access to the ulnar artery (ipsilateral or contralateral) or to the contralateral radial.
All patients will be checked during the procedure, immediately after and 24 hour post to evaluate possible vascular complications and bleeding.
Patient baseline characteristics, hospital data, comorbid conditions and complications will be recorded in a dedicated electronic case report form.
Exclusion criteria will be: lack of signed informed consent, age <18 years.
Primary End point of the study is the rate of in-hospital vascular complications and major bleeding in crossover vs non crossover groups.
Secondary End-points are:
- The rate of vascular complications or bleeding in total wrist vs femoral Group.
- The rate of minor bleeding
- Procedure duration
- Fluoroscopy time
- Number of catheters employed
- Differences among operators and Centers
Vascular complications are defined as any vascular damage clinically documented as vessel perforation, arterial-venous fistula, pseudoaneurysm, arterial dissection, retroperitoneal hematoma and compartmental syndrome. Major bleeding complications are defined according to the BARC classification, as BARC 3 (overt bleeding plus a hemoglobin drop > 3 g/dL; any transfusion with overt bleeding, cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring intravenous vasoactive agents and intracranial haemorrhage) and BARC 5 (fatal bleeding).
Minor bleeding is defined as Hematoma larger than 10 cm not requiring medical intervention (Easy III)
- Being tested
- Transradial access for percutaneous coronary procedures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transradial access for percutaneous coronary proceduresProcedure or surgery
Transradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion
| Study group | Role | What they receive |
|---|---|---|
| Crossover Group | Patients with Transradial access failure for percutaneous coronary procedures necessitating vascular crossover Receives: Procedure: Transradial access for percutaneous coronary procedures | |
| Non Crossover Group | Patients with successful transradial access for percutaneous coronary procedures Receives: Procedure: Transradial access for percutaneous coronary procedures |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vascular complications and major bleeding
The rate of in-hospital vascular complications and major bleeding in crossover vs non crossover groups
Measured: up to seven days
Secondary outcomes (1)
Minor bleeding
The rate of minor bleeding in crossover vs non crossover groups
Measured: up to seven days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2022
- Study start15 Jul 2022
- Primary completion15 Jan 2025
- Study completion16 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary AngiographyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 1,357 participants (actual)
- Target duration
- 6 Days
Sponsor and investigators
- Lead sponsor
- Ospedale Sandro Pertini, Roma
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alessandro Sciahbasi, MD, Ospedale Sandro Pertini, Roma
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05340998
- Sponsor's protocol ID
- Pertini06
- Acronym
- REPEAT
- Status last verified
- Mar 2025
- First submitted
- 14 Apr 2022
- Last updated
- 13 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radial accEss Crossover for PErcutaneous Coronary Procedures And ouTcome: the REPEAT Study
- ClinicalTrials.gov ID
- NCT05340998
- Acronym / sponsor ID
- REPEAT / Pertini06
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,357 participants (actual)
- Lead sponsor
- Ospedale Sandro Pertini, RomaUniversity, hospital or other
- Study start
- 15 Jul 2022 (actual)
- Primary completion
- 15 Jan 2025 (actual)
- Study completion
- 16 Jan 2025 (actual)
- First posted
- 22 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial access (TRA) will be screened for inclusion in this prospective observational study and patients with TRA failure necessitating vascular crossover will be included in the Registry after signing a dedicated written informed consent. A Control group of consecutive patients with radial access and without crossover will be included. Primary end point of the study is the rate of in-hospital vascular complications and major bleeding in crossover vs non crossover groups
Detailed description
All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial approach (TRA) will be screened for inclusion in this prospective observational study and patients with TRA failure necessitating vascular crossover will be included in the Registry after signing a dedicated written informed consent. A Control group of consecutive patients with radial access and without crossover will be enrolled (2:1 rate compared to crossover group to avoid possible selection bias) after signing a dedicated written informed consent.
The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion.
According to the selected secondary access, patients will be divided in two groups: patients with a secondary (or tertiary) wrist access (total wrist Group) and patients with a crossover to femoral (Femoral Group). Patients included in the total wrist group may have a secondary access to the ulnar artery (ipsilateral or contralateral) or to the contralateral radial.
All patients will be checked during the procedure, immediately after and 24 hour post to evaluate possible vascular complications and bleeding.
Patient baseline characteristics, hospital data, comorbid conditions and complications will be recorded in a dedicated electronic case report form.
Exclusion criteria will be: lack of signed informed consent, age <18 years.
Primary End point of the study is the rate of in-hospital vascular complications and major bleeding in crossover vs non crossover groups.
Secondary End-points are:
- The rate of vascular complications or bleeding in total wrist vs femoral Group.
- The rate of minor bleeding
- Procedure duration
- Fluoroscopy time
- Number of catheters employed
- Differences among operators and Centers
Vascular complications are defined as any vascular damage clinically documented as vessel perforation, arterial-venous fistula, pseudoaneurysm, arterial dissection, retroperitoneal hematoma and compartmental syndrome. Major bleeding complications are defined according to the BARC classification, as BARC 3 (overt bleeding plus a hemoglobin drop > 3 g/dL; any transfusion with overt bleeding, cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring intravenous vasoactive agents and intracranial haemorrhage) and BARC 5 (fatal bleeding).
Minor bleeding is defined as Hematoma larger than 10 cm not requiring medical intervention (Easy III)
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 6 Days
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Crossover Group | – | Procedure: Transradial access for percutaneous coronary proceduresPatients with Transradial access failure for percutaneous coronary procedures necessitating vascular crossover |
| Non Crossover Group | – | Procedure: Transradial access for percutaneous coronary proceduresPatients with successful transradial access for percutaneous coronary procedures |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with an indication to percutaneous coronary procedures performed through transradial approach
Key inclusion criteria (1 listed)
- All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial access
Key exclusion criteria (1 listed)
- Lack of signed informed consent, age <18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transradial access for percutaneous coronary proceduresTransradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion | Procedure or surgery | Crossover Group, Non Crossover Group |
Primary outcome
Vascular complications and major bleeding
Time frame: up to seven days
The rate of in-hospital vascular complications and major bleeding in crossover vs non crossover groups
1 secondary outcome
Minor bleeding
Time frame: up to seven days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2025.
Related trials for Coronary Angiography
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Randomized Prospective Trial on the Cost-Effectiveness of Photon-Counting CT Versus Energy-Integrating Detector CT in Suspected Chronic Coronary Syndrome
Computed Tomography Angiography, Coronary Artery Disease
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Not yet recruiting
Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)
Coronary In-stent Restenosis, Coronary Artery Disease
Enrolling by invitation
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Angiography and Percutaneous Coronary Intervention, run by Ospedale Sandro Pertini, Roma at 10 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vascular complications and major bleeding (time frame: up to seven days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2025.